PLEASANTON, Calif., Nov. 11, 2010 /PRNewswire/ -- Thoratec Corporation (Nasdaq: THOR ), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be hosting an investor event on Tuesday, November 16 at the American Heart Association (AHA) Scientific Sessions 2010.
Gary F. Burbach, president and chief executive officer of Thoratec, will be discussing highlights from data presentations during AHA regarding the company's HeartMate II® LVAS (Left Ventricular Assist System), as well as a review of the company's bridge-to-transplantation post-approval study, which showed survival of 90 percent at six months and 85 percent at one year.
The presentation will begin promptly at 12:30 p.m., Central Standard Time. The event will be webcast and accessible via the company's web site at www.thoratec.com , with a replay available until Tuesday, November 23.
Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's products include the HeartMate® LVAS and Thoratec® VAD (Ventricular Assist Device) with more than 15,000 devices implanted in patients suffering from heart failure. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's web site at http://www.thoratec.com .
Thoratec, the Thoratec logo, HeartMate and HeartMate II are registered trademarks of Thoratec Corporation and IVAD is a trademark of Thoratec Corporation.